Go to the list of all blogs
Harry Richardson's Avatar
published in Blogs
Oct 26, 2026
TickeronGET DAILY SIGNALS
HCA Healthcare (HCA) Climbs +8% in Recent Weeks on Resilient Volumes

HCA Healthcare (HCA) Climbs +8% in Recent Weeks on Resilient Volumes

Key Takeaways

  • HCA Healthcare shares have advanced roughly 8% over the trailing 30 days, a steady climb that leaves the stock well above its 52-week low of about $354 and below its 52-week high near $556.
  • As of late October 2026, HCA traded around $472 per share, with a market capitalization of approximately $101 billion and a price-to-earnings ratio in the mid-teens.
  • Second-quarter 2026 results came in ahead of consensus, with revenue of $20.23 billion and diluted earnings per share of $7.59, up 11% year over year.
  • Management revised full-year 2026 guidance to revenue of $77.0–$79.5 billion and diluted EPS of $28.70–$30.50, reflecting payer-mix pressure from the expiration of enhanced premium tax credits.
  • Several firms have turned more constructive on the shares, including RBC Capital (Outperform, $496 target), TD Cowen (Buy, $460), and BMO Capital (Outperform, $495).
  • For more detail, explore HCA's Price Targets, Earnings, and Forecast pages.
  • Discover top-performing automated strategies on Trending AI Robots.

Market Snapshot

HCA Healthcare's stock has moved steadily higher in recent weeks, gaining about 8% over the past 30 days on resilient hospital volumes and improving investor sentiment toward healthcare services. The shares remain in a broad recovery range, with a 52-week span of roughly $354 to $557. The company carries a trailing dividend yield near 0.7% and a beta of about 1.1, indicating slightly above-market volatility relative to the broader equity market. Analysts broadly rate the stock a Buy, with an average 12-month price target near $460, though several recently raised targets sit meaningfully higher. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Business Overview and Competitive Position

HCA Healthcare is the largest for-profit hospital operator in the United States. Headquartered in Nashville, Tennessee, the company operates approximately 190 hospitals and roughly 2,600 ambulatory sites of care, including surgery centers, freestanding emergency rooms, urgent care centers, and physician clinics, across 19 states and the United Kingdom. Its scale gives HCA meaningful cost advantages over smaller and not-for-profit rivals, supporting industry-leading operating margins.

The company benefits from long-term demographic tailwinds, including an aging population that consumes more healthcare services, and maintains strong local positions in faster-growing markets such as Florida and Texas. HCA complements its acute-care footprint with a large outpatient network and a multi-billion-dollar capital expenditure program aimed at adding inpatient beds and ambulatory capacity. It also returns capital to shareholders through dividends and share repurchases.

Recent Developments and Earnings

HCA's second-quarter 2026 report, released in late July, set the tone for the recent advance. Revenue rose 8.7% year over year to $20.23 billion, and diluted EPS climbed 11% to $7.59, both beating consensus estimates. Same-facility admissions and equivalent admissions increased 2.5% and 2.7%, respectively, while emergency room visits rose 3.6%, underscoring durable underlying demand.

The dominant headwind remains the expiration of enhanced premium tax credits, which reduced health-insurance-exchange enrollment and increased the number of uninsured patients. Management now expects an unfavorable exchange-related impact on adjusted EBITDA of roughly $1.0 billion to $1.2 billion for 2026, partially offset by incremental Medicaid supplemental payment benefits of $300 million to $500 million, including a Florida directed payment program.

Against that backdrop, analyst sentiment has improved. RBC Capital raised its price target to $496 from $435 with an Outperform rating, TD Cowen lifted its target to $460 from $431 with a Buy rating, and BMO Capital initiated coverage with an Outperform rating and a $495 target. HCA's third-quarter 2026 results are scheduled for late October, giving investors a fresh look at volume trends and cost discipline.

2026 Outlook and Key Factors to Monitor

Looking ahead, investors will focus on several factors. First, HCA's third-quarter results will provide clarity on whether resilient demand is offsetting the exchange-driven payer-mix shift. Management expects stronger adjusted EBITDA growth in the fourth quarter relative to the third, so commentary on that trajectory will be closely watched.

Policy developments also matter. Potential changes to Medicaid eligibility, work requirements, and supplemental payment programs could influence reimbursement, and HCA has indicated it is preparing through litigation and patient support. Elective surgery volumes, which have lagged emergency procedures, remain a key swing factor, as do labor costs, inflation, and interest rates. Finally, the company's cost-resiliency program, AI-enabled efficiency initiatives, and multi-billion-dollar capacity expansion will shape margins and long-term growth. These dynamics, rather than any single catalyst, are likely to drive HCA's performance through 2026.

Using AI Tools for Strategy Discovery

In my analysis of stocks like HCA, I often turn to Tickeron’s automated tools to compare performance across strategies. The Trending AI Robots section highlights a curated selection of the platform's top-performing automated trading strategies. While Tickeron offers hundreds of AI trading bots covering thousands of tickers, only the top-performing and most relevant bots appear in this featured section. These bots vary by strategy, timeframe, and performance metrics, allowing users to compare approaches across different market conditions. The page is designed to help traders and investors discover data-driven, rules-based systems rather than relying solely on discretionary decision-making. For those interested in exploring automated trading tools, Trending AI Robots offers a practical starting point.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: HCA

Contributor

Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.


HCA sees MACD Histogram crosses below signal line

HCA saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 18, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 48 instances where the indicator turned negative. In 30 of the 48 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 62%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for HCA moved out of overbought territory on November 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 48 similar instances where the indicator moved out of overbought territory. In 28 of the 48 cases, the stock moved lower in the following days. This puts the odds of a move lower at 58%.

The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on HCA as a result. In 52 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 58%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HCA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 61%.

HCA broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The 50-day moving average for HCA moved above the 200-day moving average on November 09, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a +6.25% 3-day Advance, the price is estimated to grow further. Considering data from situations where HCA advanced for three days, in 247 of 347 cases, the price rose further within the following month. The odds of a continued upward trend are 71%.

The Aroon Indicator entered an Uptrend today. In 205 of 322 cases where HCA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 64%.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is 29 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock better than average.

The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. HCA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 45 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 62 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-16.135) is normal, around the industry mean (204.532). P/E Ratio (16.380) is within average values for comparable stocks, (21.572). Projected Growth (PEG Ratio) (1.323) is also within normal values, averaging (2.498). Dividend Yield (0.006) settles around the average of (0.153) among similar stocks. P/S Ratio (1.264) is also within normal values, averaging (2.688).

Notable companies

The most notable companies in this group are DaVita (NYSE:DVA), Community Health Systems (NYSE:CYH), WW International Inc (NASDAQ:WW).

Industry description

Hospital/Nursing Management companies own and operate health care facilities. Their operations include nursing homes, acute care facilities, retirement centers and outpatient surgery centers. HCA Healthcare Inc., Alcon Inc. and Universal Health Services, Inc. are some major companies in this industry. Technology has been at the forefront of development of advanced solutions, including quicker diagnoses of complex conditions. Investments in new diagnostics, healthcare IoT, and other healthcare technologies continue to gather momentum in this industry.

Market Cap

The average market capitalization across the Hospital/Nursing Management Industry is 5.37B. The market cap for tickers in the group ranges from 20.9K to 107.17B. HCA holds the highest valuation in this group at 107.17B. The lowest valued company is NMMCF at 20.9K.

High and low price notable news

The average weekly price growth across all stocks in the Hospital/Nursing Management Industry was -12%. For the same Industry, the average monthly price growth was -12%, and the average quarterly price growth was 0%. CHE experienced the highest price growth at 0%, while NIVF experienced the biggest fall at -88%.

Volume

The average weekly volume growth across all stocks in the Hospital/Nursing Management Industry was 13%. For the same stocks of the Industry, the average monthly volume growth was 102% and the average quarterly volume growth was 58%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 49
Price Growth Rating: 59
SMR Rating: 66
Profit Risk Rating: 83
Seasonality Score: -4 (-100 ... +100)
AI Patterns 1
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a provider of health care services

Industry HospitalNursingManagement

Industry
Hospital Or Nursing Management
Address
One Park Plaza
Phone
+1 615 344-9551
Employees
320000
Web
https://www.hcahealthcare.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.